Theranostics 2020; 10(5):2172-2187. doi:10.7150/thno.38968 This issue Cite

Research Paper

Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications

Friedrich-Christian Deuschle1, Volker Morath2, André Schiefner1, Corinna Brandt1, Simone Ballke3, Sybille Reder2, Katja Steiger3, Markus Schwaiger2, Wolfgang Weber2, Arne Skerra1✉

1. Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising, Germany
2. Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, 81675 München, Germany
3. Institute of Pathology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, 81675 München, Germany

Citation:
Deuschle FC, Morath V, Schiefner A, Brandt C, Ballke S, Reder S, Steiger K, Schwaiger M, Weber W, Skerra A. Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics 2020; 10(5):2172-2187. doi:10.7150/thno.38968. https://www.thno.org/v10p2172.htm
Other styles

File import instruction

Abstract

Graphic abstract

Enhanced amino acid supply and dysregulated integrin signaling constitute two hallmarks of cancer and are pivotal for metastatic transformation of cells. In line with its function at the crossroads of both processes, overexpression of CD98hc is clinically observed in various cancer malignancies, thus rendering it a promising tumor target.

Methods: We describe the development of Anticalin proteins based on the lipocalin 2 (Lcn2) scaffold against the human CD98hc ectodomain (hCD98hcED) using directed evolution and protein design. X-ray structural analysis was performed to identify the epitope recognized by the lead Anticalin candidate. The Anticalin - with a tuned plasma half-life using PASylation® technology - was labeled with 89Zr and investigated by positron emission tomography (PET) of CD98-positive tumor xenograft mice.

Results: The Anticalin P3D11 binds CD98hc with picomolar affinity and recognizes a protruding loop structure surrounded by several glycosylation sites within the solvent exposed membrane-distal part of the hCD98hcED. In vitro studies revealed specific binding activity of the Anticalin towards various CD98hc-expressing human tumor cell lines, suggesting broader applicability in cancer research. PET/CT imaging of mice bearing human prostate carcinoma xenografts using the optimized and 89Zr-labeled Anticalin demonstrated strong and specific tracer accumulation (8.6 ± 1.1 %ID/g) as well as a favorable tumor-to-blood ratio of 11.8.

Conclusion: Our findings provide a first proof of concept to exploit CD98hc for non-invasive biomedical imaging. The novel Anticalin-based αhCD98hc radiopharmaceutical constitutes a promising tool for preclinical and, potentially, clinical applications in oncology.

Keywords: cancer theranostics, CD98hc, lipocalin, PASylation, protein engineering, tumor targeting


Citation styles

APA
Deuschle, F.C., Morath, V., Schiefner, A., Brandt, C., Ballke, S., Reder, S., Steiger, K., Schwaiger, M., Weber, W., Skerra, A. (2020). Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics, 10(5), 2172-2187. https://doi.org/10.7150/thno.38968.

ACS
Deuschle, F.C.; Morath, V.; Schiefner, A.; Brandt, C.; Ballke, S.; Reder, S.; Steiger, K.; Schwaiger, M.; Weber, W.; Skerra, A. Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics 2020, 10 (5), 2172-2187. DOI: 10.7150/thno.38968.

NLM
Deuschle FC, Morath V, Schiefner A, Brandt C, Ballke S, Reder S, Steiger K, Schwaiger M, Weber W, Skerra A. Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics 2020; 10(5):2172-2187. doi:10.7150/thno.38968. https://www.thno.org/v10p2172.htm

CSE
Deuschle FC, Morath V, Schiefner A, Brandt C, Ballke S, Reder S, Steiger K, Schwaiger M, Weber W, Skerra A. 2020. Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics. 10(5):2172-2187.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image